Atomwise vs Schrödinger (2026)
Predict the binding or simulate it, and both companies have published enough that the argument can be had on evidence rather than on claims. Atomwise built a deep convolutional network that predicts small molecule bioactivity in three dimensions and uses it to screen ultra large synthesizable libraries in place of physical high throughput screening, and it did the thing almost nobody in this category does: published the denominator, reporting how many model selected compounds were tested and how many held up. Schrodinger simulates the physics, with a larger and older independently benchmarked literature, coverage across the discovery chain and a molecule in late stage development. For a chemistry team the real question is whether your targets have the structural data physics based methods need, because where they do the simulation is the more defensible answer and where they do not, screening is the only one available.
- The method is in the peer reviewed literature rather than in marketing copy, with the core screening result published and the network patented and described rather than referred to as proprietary.
- It reports its own denominator. The screening programme published how many predictions were tested and how many held up, which is the disclosure this category almost never makes and the reason its evidence grade is the strongest here.
- Virtual screening against an ultra large synthesizable library replaces physical high throughput screening, which is a specific and measurable substitution rather than a general claim about acceleration.
- The published and independently benchmarked method literature is larger and older, and the platform spans the discovery chain rather than one screening step.
- Evidence exists at asset level as well as platform level, including a molecule from the platform in late stage development.
- It is licensed software with the broadest coverage in this category, usable in house across small molecule discovery and adjacent domains rather than accessed through a discovery collaboration.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Atomwise and Schrödinger are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Atomwise | Schrödinger |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Headquarters | San Francisco, CA | New York, NY |
| Website | atomwise.com | schrodinger.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Atomwise its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Schrödinger, Atomwise grades higher on AI Centrality. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Schrödinger its top capability grade on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and AI Governance and Bias Disclosure. Set against Atomwise, Schrödinger grades higher on several axes, including Security Certifications and Trust Center, FDA and Regulatory Status and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Atomwise or Schrödinger?
On the axes where the AI Health Index separates them, Atomwise grades higher on AI Centrality, and Schrödinger grades higher on several axes, including Security Certifications and Trust Center, FDA and Regulatory Status and AI Governance and Bias Disclosure. Schrödinger leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Atomwise and Schrödinger differ most?
The widest separation the AI Health Index records between Atomwise and Schrödinger is on AI Centrality, where Atomwise grades A and Schrödinger grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Atomwise and Schrödinger grade the same?
The AI Health Index grades Atomwise and Schrödinger the same on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
The two run on different mechanisms and should not be compared on accuracy: one is a deep convolutional network predicting bioactivity from structure, the other is physics based simulation, and Schrodinger's low AI centrality grade reflects that rather than any judgement of quality. Neither holds a located SOC 2, ISO 27001 or equivalent attestation.
Atomwise's strongest evidence is a platform level screening result rather than a clinical outcome, and no molecule from either company should be treated as evidence that the platform generalises beyond the targets already published.